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ABSTRACT 
Importance Relatives of patients with systemic lupus erythematosus (SLE) appear to 
be at higher risk of SLE and other autoimmune diseases but estimates of individual 
familial risks are largely unavailable or unreliable. Furthermore, relative contributions 
of genetic, shared and non-shared environmental factors to SLE susceptibility remain 
unclear. 
Objective To examine familial aggregation and heritability of SLE and the relative 
risks (RRs) of other autoimmune diseases in relatives of SLE patients. 
Design and setting Population-based family study using the Taiwan National Health 
Insurance (NHI) Research Database. 
Participants All individuals (n = 23,658,577) registered with the NHI in 2010, of 
whom 18,283 individuals had SLE. We identified 21,009,551 parent-child 
relationships, 17,168,340 full sibling pairs and 342,066 twin pairs. Diagnoses of SLE 
were ascertained up to December 31, 2010.  
Main Outcomes and Measures The prevalence and relative risk (RR) of SLE and 
other autoimmune diseases in relatives and spouses of SLE patients and the relative 
contributions of heritability, shared and non-shared environmental factors to SLE 
susceptibility.  
Results The RR (95% confidence interval [CI]) for SLE was 315.94 (210.66–473.82) 
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for twins of SLE patients; 23.68 (20.13–27.84) for siblings; 11.44 (9.74–13.43) for 
parents; 14.42 (12.45–16.70) for offspring and 4.44 (2.38–8.30) for spouses. The 
accountability for phenotypic variance of SLE was 43.9% for heritability, 25.8% for 
shared environmental factors and 30.3% for non-shared environmental factors. The 
RR (95% CI) in individuals with a first-degree relative with SLE was 2.66 (2.28–
3.11) for rheumatoid arthritis; 5.40 (3.37–8.65) for systemic sclerosis; 5.87 (4.89–
7.05) for primary Sjögren’s syndrome; 2.77 (1.45–5.32) for idiopathic inflammatory 
myositis; 1.68 (1.22–2.32) for type 1 diabetes mellitus; 2.58 (1.16–5.72) for multiple 
sclerosis; 2.95 (2.04–4.26) for myasthenia gravis; 1.39 (0.66–2.91) for inflammatory 
bowel diseases and 0.86 (0.43–1.71) for vasculitis. 
Conclusions and Relevance The individual risks of SLE and other autoimmune 
diseases were increased in families with SLE patients. Heritability of SLE was 
estimated to be approximately 44%. These data should be considered when 
counselling families with affected members. 
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INTRODUCTION 
Systemic lupus erythematosus (SLE) is the prototype autoimmune disease with 
features of autoantibody production, immune complex deposition and multiple target 
organ damage. SLE can affect any part of the body1 and the course of the disease is 
diverse and unpredictable.2 The prevalence of SLE ranges from 0.02% to 0.15%.3 Our 
group recently estimated that prevalence of SLE was 0.10% in the UK4 and 0.07% in 
Taiwan.5 
Early family studies have documented familial aggregation of SLE6-13 and a classic 
twin study found a 10-fold increased concordance in monozygotic compared to 
dizygotic twins.14 Furthermore, SLE is also reported to co-aggregate with other 
autoimmune diseases.10,12 The tendency of SLE and other autoimmune diseases to 
cluster within families suggests a significant role for genetic or shared environmental 
factors in the pathogenesis of autoimmune diseases. Heritability, defined as the 
proportion of the phenotypic variance explained by genetic factors, is estimated to be 
66% in SLE,15,16 suggesting a strong genetic component to its pathogenesis. 
Consequently, efforts on defining pathogenesis of SLE focus on genetic factors and 
recent genome-wide association studies (GWAS) have successfully identified over 30 
susceptibility loci for SLE.17 However, these findings account for less than 10% of 
phenotypic variation observed.18 Large unexplained heritability leads to the question 
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of the relative contribution of genetic factors to SLE susceptibility.  
Two previous studies have reported the heritability of SLE,15,16 however, both failed 
to differentiate genetic and shared environmental factors. Therefore they more 
accurately estimated ‘familial transmission’—a measure of the combined contribution 
of genetic and shared environmental factors to disease susceptibility. Such estimates 
will overestimate the heritability of SLE. In contrast to heritability, quantitative 
estimates of an individual’s risk of SLE and other autoimmune diseases if they have a 
positive family history of SLE are more useful for genetic counselling. However, 
reliable measures such as relative risks (RR) are largely unavailable or of limited 
reliability.  
Therefore, we conducted this nationwide study comprising essentially the entire 
population of Taiwan in 2010. Using genealogy and linked health information derived 
from a comprehensive database, we determined familial clustering of SLE by 
estimating risks of SLE according to specific affected kinship and assessed the 
relative contribution of genetic, shared and non-shared environmental factors to SLE 
susceptibility. In addition we estimated the relative risks of other autoimmune 
diseases associated with a family history of SLE.  
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METHODS 
Study population 
This study was approved by the Institutional Review Board of the Chang Gung 
Memorial Hospital. A cohort of all individuals registered in the Taiwan National 
Health Insurance (NHI) in 2010 was established using data from the Registry for NHI 
beneficiaries, Registry for catastrophic illness patients and datasets of ambulatory care 
expenditures and details of ambulatory case orders, all of which are parts of the 
National Health Insurance Research Database. Individuals without valid insurance 
status were excluded from analysis. The NHI coverage rate is over 99.5% in 2010.19 
Since 1995, the NHI Research Database has recorded gender, date of birth, place of 
residence, details of insurance (employment categories, sum of insurance amount, 
enrolment and discharge date), family relationships, vital status and details of clinical 
information including dates of inpatient and outpatient visits, medical diagnoses, 
medical expenditures, prescription details, vaccination status, examinations, 
operations and procedures. The National Health Research Institute acquires all the 
data from the Department of Health and Welfare and implemented the data into an 
electronic database. All the information is linked using a unique personal 
identification assigned to each resident in Taiwan. To ensure confidentiality, unique 
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personal identification is encrypted before releasing the data to researchers but the 
identification remains unique for each beneficiary in the database to facilitate internal 
linkage of records.  
Methods to identify first-degree relatives have been reported before.20 In brief, the 
registry of beneficiaries contains the identifiers of the relationships between the 
insured person (who paid the insurance fee) and his/her dependents. Only blood 
relatives and spouses are eligible for dependents of an insured person. A birth 
certificate issued by the medical facility who delivered the child or a DNA parentage 
testing for those who were not born in medical facilities is required for a child to 
register as a dependent of their parents. This allows us to establish family 
relationships (parents, offspring, full siblings, twins and spouse) using the identifiers 
and unique personal identification of parent, grandparent, children, grandchildren and 
spouse. In general, parent-offspring relationships and spouses can be identified 
directly. An algorithm allowing indirect identification of parent-offspring relationship 
is also used to maximise possible family links (for details please refer to 
supplement).20 Full siblings of an individual were identified if they had the same 
parents. Twins were full siblings with the same date of birth (± 1 day) but twin 
zygosity cannot be derived from the database. To consider the correlation among 
subjects from the same family, individuals were grouped into families according to 
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their relationships (for details of pedigree assembly please refer to supplement).  
Among 28,402,865 beneficiaries in the NHI (both alive and deceased during the 
period between 1995 and 2010) 8,186,069 individuals were registered alone without 
any identifiable relative. The remaining 20,216,796 individuals were classified into 
4,229,301 families. Overall, 21,009,551 parent-child relationships, 17,168,340 full 
sibling pairs and 342,066 twin pairs were identified. Note that each individual may 
appear multiple times in different categories of family relationships depending on 
family structure.  
Ascertainment of SLE and other autoimmune diseases 
In Taiwan, patients with suspected autoimmune diseases are referred to specialists for 
diagnosis and treatment. Patients with diagnoses of SLE, and autoimmune diseases 
included in this study (rheumatoid arthritis, systemic sclerosis, primary Sjögren’s 
syndrome, idiopathic inflammatory myositis, type I diabetes mellitus, multiple 
sclerosis, myasthenia gravis, inflammatory bowel diseases and vasculitis) are entitled 
to waive medical co-payment. Diagnostic information is sent to the insurance 
administration for a review by commissioned expert panels to confirm the diagnosis 
before approval of waivers. In general, the panel reviews the diagnosis in compliance 
with the updated classification criteria. For instance, the American College of 
Rheumatology (ACR) revised criteria for classification of SLE were used to assist the 
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review of certificate applications for SLE.21,22 The Registry for Catastrophic Illness 
Patients contains information on these patients with unique personal identification, 
diagnosis, demographics, application date, diagnosing physician and hospital and 
other administration data. We used this registry to identify patients with SLE, 
rheumatoid arthritis, systemic sclerosis, primary Sjögren’s syndrome, idiopathic 
inflammatory myositis, type I diabetes mellitus, multiple sclerosis, myasthenia gravis, 
inflammatory bowel diseases and vasculitis (for details please refer to supplements).  
Covariates 
We considered age, gender, occupation categories, income level quintiles and level of 
urbanisation of residence and family size that might confound or modify the familial 
associations. Details for socioeconomic factors were summarised in supplements.  
Statistical analysis  
The prevalence of SLE was calculated for the general population and for individuals 
with affected first-degree family members. We calculated relative risks (RRs) of SLE 
as the adjusted prevalence ratios between first-degree relatives of an individual with 
SLE and the general population. The RR estimated in this study is essentially relative 
recurrence risk according to the original Risch definition,24 which was the prevalence 
ratio between individuals with a specific type of affected relative and the general 
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population. Several established methods are available for the estimation of prevalence 
ratios, including the Breslow-Cox proportional hazards models,25 log-binomial26 and 
robust Poisson methods.27 Cox proportional hazards models are a well-recognised 
statistical technique to handle censored survival data and estimate instantaneous 
hazards ratios based on varying follow-up time. Breslow adapted the Cox models to 
estimate prevalence rate ratios in a cross-sectional study by applying an equal follow-
up time for all subjects.25 This method has been proved to produce consistent 
estimates for prevalence ratios close to true parameters.26,28 The Cox model assumes 
independence between subjects. However, family members naturally cluster with each 
other. Both the marginal model and the shared frailty model are designed to handle 
bias caused by within-family clustering. While the shared frailty model estimates 
cluster-specific hazard functions before producing joint hazard function, the marginal 
model focuses on the population-averaged hazard function.29 Previous studies have 
documented the comparability of RR and 95% confidence intervals (CIs) between the 
marginal model (given a robust sandwich method to adjust CIs)30 and the frailty 
model.29 In addition, a previous study suggests that the marginal model produces a 
more precise parameter if the proportion of families containing discordant pairs of 
disease is low as is the case in our study.31 The RR was adjusted for age, sex, 
socioeconomic factors and family size. This approach has been applied before and 
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validated previously in other diseases.32  
We calculated RRs and tetrachoric correlations for individuals with an affected first-
degree relative of any kinship and also for individual kinship (parent, offspring, 
sibling and twin). As kinship and sex of the affected relative may also influence 
familial risk, we fitted models separately according to kinship and sex of affected 
relatives (mother, father, daughter, son, sister, brother, twin sister and brother). We 
excluded twins from the sibling analyses. In addition to first-degree relatives, we also 
estimated RR for spouses. The RR was estimated for the number of affected first-
degree kinships (father, mother, son, daughter, brother, sister). In this model, we 
compared risk of SLE in individuals with one or two affected first-degree relatives 
with the risk in the general population. To measure the degree of similarity in different 
types of relatives, we estimated tetrachoric correlations for each category of first-
degree relationships stratified by sex of SLE patients and their relatives, assuming that 
there is a continuous normally-distributed liability underlying the diagnosis of SLE.  
Heritability was defined as the proportion of phenotypic variance that is attributable to 
genetic factors and the familial transmission is the proportion of genetic and shared 
environmental contribution. Familial transmission and heritability can be calculated 
using the polygenic liability model to calculate both measures.33-35 This model 
assumes a normally distributed liability of disease resulting from small and additive 
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influences from a large number of unspecified genes and environmental factors. The 
liability of the affected individuals is greater than a critical threshold, the value of 
which can be determined with the information of the disease prevalence in the 
affected and the general population.  
The familial transmission is the function of the difference of normal deviation of the 
threshold from the mean liability between individuals with affected relatives and the 
normal population (refer to supplement for full discussion of the model and 
methods).16,20 The original model assumes zero common environmental variance and 
therefore familial transmission equals heritability. To account for contributions of 
shared environmental factors to phenotypic variance, we used the spouse as a control, 
assuming that spouses share the family environment but have no close genetic 
similarity with blood family members. We restricted family history to first degree 
relatives and assumed an average of two siblings in a family.  
An alternative way to estimate heritability was based on comparing tetrachoric 
correlations, which were used as an index of phenotypic similarity, between siblings 
and spouses, assuming that they have similar shared environment but have 50% and 
0% genetic similarity.36 Heritability was calculated as: 
Heritability = 2 ×  (tetrachoric correlation for full siblings –  tetrachoric correlation for spouse).  
We further estimated the extent of familial co-aggregation of other autoimmune 
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diseases in SLE affected families by a marginal Cox proportional hazards regression 
model with an equal follow-up time for all subjects adjusting for age, sex, place of 
residence, income levels, occupation and family size. RRs of rheumatoid arthritis, 
systemic sclerosis, primary Sjögren’s syndrome, idiopathic inflammatory myositis, 
type I diabetes mellitus, multiple sclerosis, myasthenia gravis, inflammatory bowel 
diseases and vasculitis were estimated as the adjusted prevalence ratio of specified 
autoimmune diseases between individuals with a first-degree relative with SLE and 
those without SLE family history.  
All tests of statistical hypothesis were done on the 2-sided 5% level of significance. 
All analyses were performed using SAS v. 9.3 (SAS institute, Cary, NC).
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RESULTS 
SLE prevalence in individuals with affected first-degree family members versus 
the general population 
The study population comprised of 23,658,577 individuals enrolled in NHI in Taiwan 
in 2010. Among them 18,283 patients had a diagnosis of SLE, giving a crude 
prevalence of 0.08%. Women had a significantly higher prevalence (0.14%) than men 
(0.02%) with a female:male ratio of 7 (Table 1). Overall 19,085,610 (80.67%) 
individuals had at least one known first-degree relative. The proportions of 
individuals in the study population with known parent, children, siblings and twins 
were 51.30%, 38.24%, 42.16% and 1.10%, respectively. In the general population of 
Taiwan in 2010, 45,718 (0.19%) individuals had at least one first-degree relative with 
SLE: 20,343 with affected parents, 12,435 with affected offspring, 13,115 with 
affected sibling and 101 with affected twins. Among the individuals with affected 
family members, 607 had SLE, giving a prevalence of 1.33%. For individuals with 
affected first-degree relatives with SLE the age-specific prevalence of SLE is 
significantly higher than the age-specific prevalence in the general population (Figure 
1).  
Relative risks for SLE in individuals with affected first-degree relatives 
Prevalence (recurrence risk) of SLE in individuals with affected first-degree relatives 
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of specific types is shown in Table 2. Overall, having an affected first-degree relative 
with SLE was associated with an adjusted RR of 16.92 (15.23–18.80). Table 2 also 
presents adjusted RR for SLE and 95% CIs for different affected first-degree relatives 
stratified by sex. Overall, individuals with affected relatives of female, male and both 
genders had respective RRs (95% CIs) for SLE of 16.31 (14.60–18.23), 20.35 (16.01–
25.87) and 65.24 (27.36–155.55). Although it seems that the gender of affected 
relatives did not influence RR, point estimates in table 2 suggests that there may be 
trends related to gender, in particular men with a male affected relative tend to have a 
higher RR. 
The RRs (95% CIs) for SLE were associated with the degree of genetic distance 
between family relatives. RRs were 315.94 (210.66–473.82) for co-twins (with 
highest genetic similarity) of SLE patients; 23.68 (20.13–27.84) for siblings; 11.44 
(9.74–13.43) for parents; 14.42 (12.45–16.70) for offspring and 4.44 (2.38–8.30) for 
spouses (without genetic similarity). In addition, the RRs increased with the number 
of types of affected first-degree relatives. Compared with the general population, 
individuals with one type of affected first-degree relative had a RR of 17.04 (95% CI, 
15.31–18.96) and those with two or more had a RR of 35.09 (95% CI, 14.89–82.70) 
for SLE. 
Familial resemblance and heritability of SLE  
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Overall, tetrachoric correlation for first-degree relatives was 0.33 (0.32–0.34).   
Tetrachoric correlations were substantially higher for first-degree relatives compared 
to those for spouses (table 2). Tetrachoric correlation (95% CI) was estimated to be 
0.59 (0.54–0.64) for twins; 0.35 (0.33–0.36) for full siblings; 0.27 (0.25–0.29) for 
parents; and 0.25 (0.23–0.26) for offspring and 0.07 (0.02–0.11) for spouses. Using a 
threshold liability model we estimated the accountability for phenotypic variance of 
SLE was 43.9% for genetic factors (heritability), 25.8% for shared environmental 
factors and 30.3% for non-shared environmental factors. By comparing tetrachoric 
correlations between siblings and spouses, heritability was estimated to be 56.0%. 
Co-aggregation of other autoimmune diseases 
Table 3 presents adjusted RR (95% CI) other autoimmune diseases in individuals with 
affected first-degree relatives compared to the general population. The RR (95% CI) 
in individuals with a first-degree relative with SLE was 2.66 (2.28–3.11) for 
rheumatoid arthritis; 5.40 (3.37–8.65) for systemic sclerosis; 5.87 (4.89–7.05) for 
primary Sjögren’s syndrome; 2.77 (1.45–5.32) for idiopathic inflammatory myositis; 
1.68 (1.22–2.32) for type 1 diabetes mellitus; 2.58 (1.16–5.72) for multiple sclerosis; 
2.95 (2.04–4.26) for myasthenia gravis; 1.39 (0.66–2.91) for inflammatory bowel 
diseases and 0.86 (0.43–1.71) for vasculitis. 
Sensitivity analysis 
 18 
We did a sensitivity analysis using rheumatologist-based diagnosis as an alternative 
diagnosis. Using this diagnosis, we identified 36,431 SLE patients and found a higher 
prevalence of SLE at 0.15%, probably due to the inclusion of patients with less severe 
disease of incomplete lupus. Overall, a family history of SLE was associated with a 
RR of 16.74 (95% CI, 15.77–17.77) for SLE. The RR (95% CI) for SLE was 22.35 
(20.31–24.60) for siblings; 6.22 (4.77–8.12) for spouses. The heritability for SLE was 
41.7% based on these parameters and the threshold liability model.   
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DISCUSSION 
The pathogenesis of SLE is multifactorial including genetic, environmental factors 
and abnormalities of both the innate and the adaptive immunity.37 Genetic 
predisposition plays a crucial role in susceptibility and environmental exposure can 
cause epigenetic change,38 or trigger activation of innate and adaptive immune 
response to induce or accelerate the development of SLE in susceptible individuals.39  
Strong familial aggregation in SLE has been reported but to the best of our knowledge 
this is the first population-based study investigating the familial aggregation of SLE 
and co-aggregation of other autoimmune diseases in first-degree relatives of people 
with SLE. We found that first-degree relatives of people with SLE have a 17-fold 
increased risk of SLE compared to the general population and genetic relatedness is 
associated with the magnitude of risk of SLE. Gender differences in familial risks are 
not apparent despite men with a male affected relative tending to have a higher 
relative risk.   
Heritability in this study was estimated to be 44%, which is significantly lower than 
previous estimates of 66%.15,16 However, both previous studies did not find shared 
environmental contribution to the risk of SLE. The extensive family data in our study 
indicate that shared environmental factors also contribute to SLE. To estimate 
heritability of SLE, we compared liability threshold among individuals with an 
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affected sibling and individuals with an affected spouse to that of the general 
population. Since spouses only share the family environment but not genetic 
closeness, the differences in liability threshold between siblings and spouse are 
contributed to by heritability. We further estimated heritability using methods based 
on the tetrachoric correlation of disease status and this gave a slightly higher estimate 
of heritability (56%). The difference between estimates of heritability using different 
methods is probably due to the tetrachoric correlation coefficient not adjusting for 
other potential confounders. Therefore, our findings support the contention that 
familial factors are predominant contributors to SLE susceptibility and that genetic 
factors explain approximately half of the phenotypic variance of SLE. 
Previous studies have documented familial aggregation of SLE. One study surveying 
570 SLE patients in the US found that 27% of the patients had a family history of 
autoimmune diseases.40 Another US study reported that 10% of SLE patients had 
affected first-degree relatives compared to only 1% of controls.41 A tendency for 
familial aggregation of autoimmune diseases other than just SLE has also been 
suggested. In a multicentre study of 1,177 patients with SLE in 9 Latin American 
countries 97 had at least one relative with SLE and the sibling recurrence risk ratio 
was 29.12 Furthermore, one of previous twin studies, comprising 107 twin pairs, found 
a concordance rate of 24% in monozygotic twins comparing to only 2% in dizygotic 
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twins.14 The differences reported in the current study from earlier published research 
may be attributed to study design, including sampling, case ascertainment and 
analytical approach. Previous reports are often based on less robust sampling 
strategies and case ascertainment such as hospital records, self-reported diagnosis and 
disease registries, therefore limiting generalisability. In contrast, our study used the 
entire national population of Taiwan and the case definition of SLE and other 
autoimmune diseases are based on physician-diagnoses which were scrutinised by 
expert panels.  
Although recent efforts using GWAS have identified over 30 susceptibility loci for 
SLE,17 these account for less than 10% of phenotypic variation observed.18 Previous 
studies generally attribute this apparent gap to (1) undiscovered genetic variances; (2) 
a heritable epigenetic component or structural variation;42 and (3) gene-gene 
interactions among known or undiscovered loci.43 Another possible explanation that 
has been suggested for complex diseases such as Crohn’s disease suggests that a 
proportion of heritability may remain hard to detect because of contributions from 
rare variants.44 Therefore our updated estimate of heritability, which is not as high as 
previously reported, could partly explain the gap between observed and theoretical 
variation. 
A family history of SLE is also a risk factor for primary Sjögren’s syndrome, systemic 
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sclerosis, rheumatoid arthritis, multiple sclerosis, myasthenia gravis and type 1 
diabetes mellitus. Previous studies also report that families with SLE patients are 
enriched with cases of rheumatoid arthritis, autoimmune thyroiditis, systemic 
sclerosis and polymyositis.12 These findings suggest that these autoimmune diseases 
share part of the pathogenesis of SLE but the extents of overlapping contributors to 
disease manifestation are different. This theory is partly supported by the findings that 
some immune-mediated disease risk single nucleotide polymorphisms (SNPs) are 
associated with multiple autoimmune diseases.45  
There are several limitations to the present study. Firstly, the classification of cases 
was based purely on the diagnosis recorded in the registry of patients with 
catastrophic illnesses. We do not have detailed information on clinical findings, 
laboratory testing, and examinations to verify the diagnosis according to formal 
classification criteria for SLE. Nevertheless, issuance of a catastrophic illness 
certificate requires strong medical evidence for a diagnosis of SLE that is agreed by 
an expert panel, and applications for these certificates are submitted almost 
exclusively by rheumatologists. Therefore our case definitions are stringent. However, 
patients with less severe disease or incomplete lupus are not eligible for a certificate 
so could not have been identified as cases. Furthermore, an alternative case definition, 
using rheumatologist diagnosis as a case definition for SLE resulted in very similar 
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results to the primary analysis. Secondly, zygosity of twins is not recorded in the 
database; therefore we cannot estimate heritability using a classic twin study design. 
However, we utilised two of four methods most commonly used to estimate 
heritability46 and found very similar results. Thirdly, because we estimated heritability 
using the threshold liability model the results are subject to the assumption that 
diseases result from underlying liability that is normally distributed in the population. 
Nevertheless, although this is a potential caveat, data on other diseases such as 
schizophrenia support the validity of this model.47 Fourthly, we cannot account for the 
effects of assortative mating whereby spouses are more similar for a phenotype than 
they would be if mating occurred at random in the population. If this assortment is not 
negligible, heritability could have been underestimated.48 However, our model has a 
theoretical limit of heritability, which cannot be higher than that of familial 
transmission. Therefore only if shared environmental factors were non-existent would 
the heritability of SLE approach previous estimates. Fifthly, this study was restricted 
to Taiwan and it is possible that different findings may occur in different populations 
and in different environments. Therefore further studies in other countries are required 
to determine the generalisability of the findings. Furthermore, cluster effect – 
correlation between family members may affect the estimate of RR and its 95% CI. 
There are two approaches to adjust this effect, the marginal and frailty models.29 The 
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frailty model estimates a cluster-specific hazard function through latent variables 
common to the same cluster whereas the marginal model focuses on the marginal 
distribution of the function while separately modelling the association among 
responses from the same cluster. The current penalised partial likelihood approach to 
fit the frailty model fails due to a huge matrix caused by a very large number of 
families involved in our study (4.22 million). However, we randomly selected 10,000 
families to compare the results from these two models. We found that the familial 
risks for SLE was 13.92 (95% CI, 6.23 – 31.14) by the marginal model and 12.24 
(5.37– 26.29) by the frailty model, suggesting that the two models provide similar 
results. This is consistent with the literature concerning the comparability of these two 
models.29,30  
In conclusion, this first nationwide family study confirms that in Taiwan a family 
history of SLE is one of the strongest risk factor for SLE. Differential risk associated 
with different kinships suggests a strong genetic component in the susceptibility of 
SLE. A family history of SLE also exerts an increased risk of other autoimmune 
diseases. These findings may help inform the design of future studies of familial and 
genetic risk of SLE and may also be useful in counselling families with SLE patients.   
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Figure legend 
Figure 1. Age specific prevalence of SLE in individuals with a first-degree relative with 
SLE (dashed line) and in the general population (solid line) in Taiwan in 2010.  
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Tables 
Table 1. Baseline characteristics of individuals with affected relatives with SLE and the general population 
 
  
Variables 
Women Men 
≥1 affected 
relatives 
General 
population 
p ≥1 affected 
relatives  
General 
population 
p 
No. 22,494 11,926,513 NA 23,224 11,732,064 NA 
Age (years) (mean ± standard deviation) 33.9 ± 18.1 37.9 ± 20.4 <0.001 33.8 ± 18.4 37.1 ± 20.6 <0.001 
SLE, No. (%) 516 (2.29) 16,385 (0.14) <0.001 91 (0.39) 1,898 (0.02) <0.001 
Place of residence, No.  (%)       
Urban  14,360 (63.84) 7,197,968 (60.35) <0.001 13,729 (59.12) 6,737,087 (57.42) <0.001 
Suburban  6,120 (27.21) 3,209,020 (26.91)  6,663 (28.69) 3,372,637 (28.75)  
Rural  1,664 (7.40) 1,087,991 (9.12)  1,799 (7.75) 1,098,656 (9.36)  
Unknown 350 (1.56) 431,534 (3.62)  1,033 (4.45) 523,684 (4.46)  
Income levels, No.  (%)       
Quintile 1  
3,420 (15.20) 1,960,003 (16.43) <0.001 3,653 (15.73) 2,117,136  
(18.05) 
<0.001 
Quintile 2  3,524 (15.67) 1,839,576 (15.42)  3,088 (13.30) 1,495,341 (12.75)  
Quintile 3  5,536 (24.61) 3,161,293 (26.51)  6,107 (26.30) 3,135,633 (26.73)  
Quintile 4  5,089 (22.62) 2,252,173 (18.88)  5,152 (22.18) 2,294,886 (19.56)  
Quintile 5 4,569 (20.31) 2,274,656 (19.07)  4,190 (18.04) 2,163,222 (18.44)  
 Unknown 356 (1.58) 438,812 (3.68)  1,034 (4.45) 525,846 (4.48)  
Occupation, No.  (%)       
Dependents of the insured individuals 9,269 (41.21) 4,924,319 (41.29) <0.001 8,977 (38.65) 4,285,015 (36.52) <0.001 
Civil servants, teachers, military personnel and 
veterans  
776 (3.45) 401,734 (3.37)  946 (4.07) 582,717 (4.97)  
Non-manual workers and professionals  6,615 (29.41) 3,031,660 (25.42)  7,187 (30.95) 3,325,548 (28.35)  
Manual workers 4,197 (18.66) 2,612,534 (21.91)  3,925 (16.90) 2,272,550 (19.37)  
Other  1,637 (7.28) 956,266 (8.02)  2,189 (9.43) 12,66234 (10.79)  
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Table 2. Relative risks and tetrachoric correlation for SLE in different kinships. 
Type of affected 
relative 
Sex of affected  
relative 
Sex of individual No. of cases Prevalence (%) 
Relative recurrence ratio 
(95% confidence interval)a 
Tetrachoric correlation 
(95% confidence interval) 
Any Female Female 455 2.27 15.98 (14.15–18.06) 0.34 (0.33–0.35) 
  Male 72 0.35 20.51 (16.36–25.73) 0.32 (0.29–0.35) 
  All 527 1.29 16.51 (14.78–18.42) 0.32 (0.31–0.34) 
 Male Female 66 2.62 18.25 (14.33–23.23) 0.30 (0.27–0.33) 
  Male 22 0.85 49.23 (27.87–86.94) 0.36 (0.31–0.41) 
  All 88 1.72 21.69 (17.17–27.40) 0.30 (0.28–0.33) 
 All Female 516 2.29 16.14 (14.44–18.04) 0.35 (0.33–0.36) 
  Male 91 0.39 23.08 (18.57–28.68) 0.34 (0.31–0.36) 
  All 607 1.33 16.92 (15.23–18.80) 0.33 (0.32–0.34) 
Parent Female  
(mother) 
Female 125 1.46 13.28 (11.19–15.75) 0.25 (0.23–0.27) 
 Male 25 0.26 18.10 (12.15–26.96) 0.25 (0.21–0.30) 
  All 150 0.82 13.89 (11.86–16.27) 0.24 (0.22–0.26) 
 Male 
(father) 
Female 18 1.79 16.42 (10.16–26.54) 0.24 (0.18–0.29) 
 Male 6 0.53 36.94 (16.75–81.44) 0.28 (0.20–0.37) 
  All 24 1.12 19.02 (12.62–28.65) 0.23 (0.19–0.28) 
 All Female 143 1.50 13.60  (11.58–15.98) 0.26 (0.24–0.28) 
  Male 31 0.29  20.09 (14.11–28.61) 0.27 (0.23–0.31) 
  All 174 0.86 14.42 (12.45–16.70) 0.25 (0.23–0.26) 
Offspring Female 
(daughter) 
Female 106 1.85 10.53 (8.73–12.71) 0.27 (0.25–0.30) 
 Male 14 0.27 13.68 (8.12–23.06) 0.25 (0.19–0.30) 
  All 120 1.10 10.89 (9.12–12.97) 0.26 (0.24–0.29) 
 Male 
(son) 
Female 20 2.36 13.62 (8.85–20.96) 0.26 (0.21–0.31) 
 Male 5 0.66 32.93 (13.79–78.64) 0.30 (0.21–0.39) 
  All 25 1.56 15.56 (10.61–22.83) 0.27 (0.22–0.31) 
 All Female 125 1.91 10.89 (9.17–12.94) 0.28 (0.26–0.30) 
  Male 19 0.32 16.23 (10.40–25.34) 0.27 (0.22–0.32) 
  All 144 1.16 11.44 (9.74–13.43) 0.27 (0.25–0.29) 
Sibling Female 
(sister) 
Female 200 3.46 22.21 (18.40–26.80) 0.36 (0.34–0.38) 
 Male 35 0.58 31.51 (22.75–43.64) 0.34 (0.30–0.38) 
  All 235 2.00 23.22 (19.65–27.45) 0.34 (0.33–0.36) 
 Male 
(brother) 
Female 28 4.19 26.60 (18.57–38.12) 0.33 (0.28–0.37) 
 Male 5 0.72 38.30 (11.84–123.91) 0.31 (0.22–0.39) 
  All 33 2.42 27.92 (19.61–39.75) 0.31 (0.27–0.35) 
 All Female 228 3.54 22.71 (19.15–26.93) 0.37 (0.35–0.39) 
  Male 39 0.58 31.55 (22.78–43.71) 0.34 (0.30–0.38) 
  All 267 2.04 23.68 (20.13–27.84) 0.35 (0.33–0.36) 
Twin Female Female 25 34.25 274.10 (177.87–422.39) 0.58 (0.52–0.64) 
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 (twin sister) Male 0 0 N/Ab N/Ab 
  All 25 30.49 266.79 (173.36–410.58) 0.58 (0.53–0.64) 
 Male 
(twin brother) 
Female 0 0 N/Ab N/Ab 
 Male 6 35.29 2682.75 (1130.46–6366.56) 0.68 (0.58–0.78) 
  All 6 31.58 1329.02 (402.51–4393.21) 0.55 (0.45–0.66) 
 All Female 25 33.33 267.21 (173.07–412.58) 0.57 (0.52–0.63) 
  Male 6 23.08 1381.43 (504.64–3781.62) 0.63 (0.53–0.73) 
  All 31 30.69 315.94 (210.66–473.82) 0.59 (0.54–0.64) 
Spouse All All 15 0.18 4.44 (2.38–8.30) 0.07 (0.07–0.22) 
a Adjusted for  age, gender, place of residence, quintiles of income levels, occupation and family size. 
b Not applicable (N/A) because of no SLE cases with affected twin.  
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Table 3. Relative risks of other autoimmune diseases in individuals with affected first-degree relatives. 
 
 
 
 
Autoimmune diseases Sex  
With affected relatives General population Relative risk 
(95% confidence interval)a No. of cases Prevalence (%) No. of cases Prevalence (%) 
Rheumatoid arthritis Female 126 0.56 29577 0.25 2.77 (2.33–3.30) 
 Male 31 0.13 7905 0.07 2.29 (1.61–3.24) 
 All 157 0.34 37482 0.16 2.66 (2.28–3.11) 
Primary Sjögren’s syndrome Female 106 0.47 11462 0.10  5.90 (4.87–7.14) 
 Male 11 0.05 1292 0.01 5.52 (3.07–9.94) 
 All 117 0.26 12754 0.05 5.87 (4.89–7.05) 
Systemic sclerosis Female 14 0.062 1495 0.013  5.75 (3.42–9.66) 
 Male 3  0.013 396 0.003 4.18 (1.36–12.82) 
 All 17 0.037 1891 0.008 5.40 (3.37–8.65) 
Idiopathic inflammatory myositis 
Female 6 0.027 1260 0.011 2.74 (1.23–6.07) 
Male 3 0.013 548 0.005 2.84 (0.91–8.80) 
 All 9 0.020 1808 0.008 2.77 (1.45–5.32) 
Type I diabetes mellitus 
Female 20 0.09 5416 0.05 1.66 (1.07–2.57) 
Male 19 0.08 4865 0.04 1.71 (1.07–2.73) 
 All 39 0.09 10281 0.04 1.68 (1.22–2.32) 
Multiple sclerosis Female 6 0.027 965 0.008 3.40 (1.54–7.53) 
 Male 0 0 287 0.002 N/A 
 All 6 0.013 1252 0.005 2.58 (1.16–5.72) 
Myasthenia gravis 
Female 19 0.08 3472 0.03 3.10 (1.98–4.84) 
Male 11 0.05 2250 0.02 2.71 (1.50–4.87) 
 All 30 0.07 5722 0.02 2.95 (2.04–4.26) 
Inflammatory bowel diseases 
Female 3 0.01 1027 0.01 1.68 (0.54–5.21) 
Male 4 0.02 1688 0.01 1.23 (0.46–3.26) 
 All 7 0.02 2715 0.01 1.39 (0.66–2.91) 
Vasculitis Female 5 0.02 1843 0.02 1.40 (0.58–3.36) 
 Male 3 0.01 2910 0.02 0.52 (0.17–1.61) 
 All 8 0.02 4753 0.02 0.86 (0.43–1.71) 
 a Adjusted for  age, gender, place of residence, quintiles of income levels, occupation and family size.  
b Not applicable (N/A) because of no male multiple sclerosis cases with affected first-degree relatives. 
 
